InsidersTradesSigma
Follow the CHIMERIX INC share price and the full management transaction log of the company, a publicly traded company based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, CHIMERIX INC has logged 67 insider filings. The latest transaction was disclosed on 21 April 2025 (Disposition). Among the most active insiders: Jakeman David. All data is free.
67
Insider Decl.
n/a
Thresholds
€308,151
14 ops.
Buy Volume
€44m
28 ops.
Sell Volume
40Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 21 April 2025
Declarations67 total
60,828 shares@ US$8.55100.0% of flowCommon StockSEC:0001415889-25-011079:0
87,000 shares@ US$8.5560.5% of flowCommon StockSEC:0001415889-25-011081:0
173,852 shares@ US$8.5599.0% of flowCommon StockSEC:0001415889-25-011074:0
72,055 shares@ US$8.5594.1% of flowCommon StockSEC:0001415889-25-011069:0
181,541 shares@ US$8.5598.8% of flowCommon StockSEC:0001415889-25-011073:0
35,150 shares@ US$8.5590.2% of flowCommon StockSEC:0001415889-25-011075:0
156,209 shares@ US$8.5591.1% of flowCommon StockSEC:0001415889-25-011070:0
40,000 shares@ US$8.5563.0% of flowCommon StockSEC:0001415889-25-011076:0
216,689 shares@ US$8.5599.6% of flowCommon StockSEC:0001415889-25-011064:0
630,828 shares@ US$8.5594.8% of flowCommon StockSEC:0001415889-25-011066:0
2,260 shares@ US$4.51130.7% of flowCommon StockSEC:0001415889-25-004212:0
300 shares@ US$4.5320.1% of flowCommon StockSEC:0001415889-25-004213:0
7,370 shares@ US$4.51590.6% of flowCommon StockSEC:0001415889-25-004218:0
3,065 shares@ US$4.5021.0% of flowCommon StockSEC:0001415889-25-004219:0
1,600 shares@ US$4.51650.4% of flowCommon StockSEC:0001415889-25-004216:0
2,800 shares@ US$4.09650.9% of flowCommon StockSEC:0001415889-25-002500:0
2,350 shares@ US$4.10050.2% of flowCommon StockSEC:0001415889-25-002496:0
1,015 shares@ US$4.110.3% of flowCommon StockSEC:0001415889-25-002498:0
45,925 shares0Common StockSEC:0001415889-25-001223:0
41,667 shares0Common StockSEC:0001415889-25-001220:0
10,855 shares0Common StockSEC:0001415889-25-001222:0
54,275 shares0Common StockSEC:0001415889-25-001221:0
41,667 shares0Common StockSEC:0001415889-25-001224:0
150,000 shares0Common StockSEC:0001415889-25-001219:0
60,000 shares0Common StockSEC:0001415889-24-025802:0
25 of 67 declarations
关于 CHIMERIX INC
Chimerix Inc. (NASDAQ: CMRX) 是一家在美国纳斯达克市场上市的美国生物制药公司，总部位于北卡罗来纳州达勒姆。对于投资者而言，该公司是一家专注于开发严重疾病新型疗法的专业医疗保健公司，其目前的战略定位集中于肿瘤学和罕见病药物开发。Chimerix成立于2000年，最初围绕抗病毒技术建立其平台，随后逐渐将其产品组合转向更高价值的临床项目，尤其是在肿瘤学领域。([ir.chimerix.com](https://ir.chimerix.com/news-releases/news-release-details/chimerix-acquires-oncoceutics-expand-pipeline-late-stage?utm_source=openai)) 如今，Chimerix的核心价值驱动因素是其主要资产dordaviprone，也称为ONC201。公司将其描述为一种一流的小分子咪唑酮，正在开发用于H3 K27M突变弥漫性胶质瘤，这是一种罕见且高度侵袭性的脑肿瘤，存在巨大的未满足医疗需求。2025年2月，Chimerix宣布FDA已接受其新药申请并授予优先审查，PDUFA目标行动日期为2025年8月18日。这一监管里程碑是投资案例的核心，如果获得批准，可能会带来变革性的影响。([ir.chimerix.com](https://ir.chimerix.com/news-releases/news-release-details/chimerix-announces-fda-acceptance-and-priority-review-new-drug?utm_source=openai)) 从竞争角度来看，Chimerix是一家高度专注的生物技术公司，而非多元化的制药集团。其狭窄的管线增加了集中风险，但如果dordaviprone商业成功，也为公司带来了显著的经营杠杆。管理层强调该药物有望成为首个获批专门用于复发性H3 K27M突变弥漫性胶质瘤的疗法，这将在一个虽小但医疗需求紧迫的市场中建立重要的先发优势。([ir.chimerix.com](https://ir.chimerix.com/news-releases/news-release-details/chimerix-announces-fda-acceptance-and-priority-review-new-drug?utm_source=openai)) 历史上，Chimerix最初是一家抗病毒公司，围绕口服抗病毒候选药物如brincidofovir进行开发。随着时间的推移，公司将资本重新分配到肿瘤学领域，特别是通过2021年收购Oncoceutics，将ONC201纳入其产品组合。它还在2022年将TEMBEXA货币化，这突显了其战略重心转向其主要的临床肿瘤学资产。这一系列事件表明，公司有意识地缩小了范围，以最大限度地提高围绕其最有前途的项目创造价值的可能性。([ir.chimerix.com](https://ir.chimerix.com/news-releases/news-release-details/chimerix-acquires-oncoceutics-expand-pipeline-late-stage?utm_source=openai)) 从地理上看，Chimerix主要在美国运营，并与美国及海外的临床基地合作开展其开发项目。2025年最新的公司通讯强调了监管进展和潜在商业发布的准备工作。对于市场参与者而言，Chimerix应被视为一家由催化剂驱动的生物技术公司，其估值可能高度受FDA结果、临床数据以及H3 K27M突变弥漫性胶质瘤商业化执行情况的影响。([ir.chimerix.com](https://ir.chimerix.com/news-releases/news-release-details/chimerix-announces-fda-acceptance-and-priority-review-new-drug?utm_source=openai))
